Search

everythinglearnresearchcommunity

for

Search:↓

Baricitinib helps long-term hair regrowth in severe alopecia areata patients.

AZD6244 treatment causes skin aging effects by depleting skin stem cells.

Tofacitinib helped some young children with severe hair loss grow their hair back without bad side effects.

A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.

Gefitinib and Sasam-Kyeongokgo together significantly reduce cancer growth and improve immune response in mice.

Adding a second method to PROTACs could improve cancer treatment.

Ruxolitinib treatment led to unexpected hair regrowth in a patient with alopecia universalis.

Tofacitinib effectively regrows hair in alopecia areata patients, especially in younger individuals, with manageable side effects.

Baricitinib successfully treated severe hair loss.

Baricitinib helped regrow hair in patients with severe alopecia areata after other treatments failed.

Tofacitinib helped a patient regrow hair after 40 years of total hair loss.

Baricitinib effectively treats severe alopecia for up to 104 weeks.

Tofacitinib is a promising treatment for children with rheumatic diseases.

Upadacitinib helped regrow hair in a severe alopecia areata patient but stopping treatment caused hair loss to return.

Baricitinib might help treat hair loss in lupus patients, but more research is needed.

Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.

Upadacitinib improved hair regrowth and quality of life in alopecia areata patients with minimal side effects.

Baricitinib may effectively treat lichen planopilaris.

The model successfully predicted new uses for existing drugs, like using certain hormonal and heart medications for respiratory and Parkinson's diseases, and a cancer drug for diabetes.

Vemurafenib can cause scalp issues but can be managed without changing the dose.

JAK inhibitors may help treat Alopecia Areata but need careful monitoring due to side effects.

Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.

Topical Ruxolitinib may safely treat severe hair loss.

Valproic acid and crocin together boost cell growth and may help treat nerve injuries.

Upadacitinib effectively treated severe hair loss in a child.

New melanoma treatments can cause skin side effects, including skin cancer and rashes, but combining treatments may reduce these risks.

Canagliflozin helps overcome progestin resistance in certain endometrial cancer cells.

Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.

Pembrolizumab can cause serious liver issues, requiring close monitoring and early treatment.